Asset profile
Almonertinib
Small molecule
Evidence outlook · lead readout
ACROSS2 (NCT04500717) · Non Small Cell Lung Cancer
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
ACROSS2 (NCT04500717): Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
102 competitors in this universe: 41 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Almonertinib: this drug | Phase 3 | Small molecule | EGFR | ||
| Gefitinib | Approved | Small molecule | EGFR | ||
| Lazertinib | Approved | Small molecule | EGFR | ||
| Osimertinib (Tagrisso) | Approved | Small molecule | EGFR | ||
| Sunvozertinib | Approved | Small molecule | EGFR | ||
| Alflutinib | Phase 3 | Small molecule | EGFR | ||
| Befotertinib | Phase 3 | Small molecule | EGFR | ||
| BPI-7711 | Phase 3 | Small molecule | EGFR | ||
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | ||
| FHND9041 | Phase 3 | Small molecule | EGFR | ||
| Icotinib | Phase 3 | Small molecule | EGFR | ||
| JMT101 | Phase 3 | Monoclonal antibody | EGFR | ||
| Limertinib | Phase 3 | Small molecule | EGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR) | ||
| PLB1004 | Phase 3 | Small molecule | EGFR | ||
| SH-1028 | Phase 3 | Small molecule | EGFR | ||
| TY-9591 | Phase 3 | Small molecule | EGFR |
…and 87 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
35 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (6)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
May 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (3)
October 2028 (1)
What to watch
2029 (2)
2032 (1)
November 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.